Henry D A, Somerville K W, Kitchingman G K, Holmes I B, Tobert J A, Langman M J
Br J Clin Pharmacol. 1985 Aug;20(2):133-6. doi: 10.1111/j.1365-2125.1985.tb05043.x.
Submaximal dose pentagastrin tests conducted in normal male volunteers with L-643.441, a novel histamine H2-receptor antagonist, indicate that it is a potent and long-acting inhibitor of gastric acid secretion. The effect appears dose-dependent and single doses of 50 mg are sufficient to reduce secretory potential by at least 50% when examined 24 h after drug administration. No adverse effects attributable to treatment were observed.